As introduced previously, TIMP2 was related to TMB, MSI, and neoantigen in varying degrees, providing a theoretical basis for directing patient-specific cancer immunotherapy optimizing clinical benefit of current immunotherapy. This evidence concerns the gene TIMP2 and cancer.